Silexion Therapeutics Corp 10-K Cybersecurity GRC - 2025-03-18

Page last updated on March 19, 2025

Silexion Therapeutics Corp reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2025-03-18 16:24:44 EDT.

Filings

10-K filed on 2025-03-18

Silexion Therapeutics Corp filed a 10-K at 2025-03-18 16:24:44 EDT
Accession Number: 0001178913-25-000887

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C . Cybersecurity Risk Management and Strategy We have implemented and maintain an information security program designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data including intellectual property, clinical trial participant and patient-related data, and confidential information that is proprietary, strategic or competitive in nature. We believe our information security program is appropriate for a company of our size and stage of development, taking into account our operations and risks. Our cybersecurity policies and processes include: - Mechanisms, controls, and technologies designed to prevent or mitigate system intrusion or data loss, theft, misuse, or other security incidents or vulnerabilities and maintain a stable and secure information technology environment. - Information security policies, network and device security, encryption standards, risk management, as well as security tools such as malware protection and secure authentication tools. - We conduct ongoing monitoring of critical systems for any compromised or potentially compromised accounts, and conduct regular trainings for our employees and senior management on cyber and information security. Governance The audit committee of our Board of Directors oversees and reviews our cybersecurity risks and the steps management has taken to protect against threats to our information systems and security. Our leadership team, including our Chief Executive Officer and Chief Financial Officer, provides periodic reports to our Board of Directors and the audit committee, as applicable. To date, we have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. 69


Company Information

NameSilexion Therapeutics Corp
CIK0002022416
SIC DescriptionBiological Products, (No Diagnostic Substances)
TickerSLXN - NasdaqSLXNW - Nasdaq
Website
Category
Emerging growth company
Fiscal Year EndDecember 30